Filippo Caldini - Establishment Labs Interim President
| ESTA Stock | USD 39.67 0.21 0.53% |
President
Filippo Caldini is Interim President of Establishment Labs Holdings
| Age | 59 |
| Address | Building B15 and 25, Alajuela, Costa Rica |
| Phone | 506 2434 2400 |
| Web | https://www.establishmentlabs.com |
Filippo Caldini Latest Insider Activity
Tracking and analyzing the buying and selling activities of Filippo Caldini against Establishment Labs stock is an integral part of due diligence when investing in Establishment Labs. Filippo Caldini insider activity provides valuable insight into whether Establishment Labs is net buyers or sellers over its current business cycle. Note, Establishment Labs insiders must abide by specific rules, including filing SEC forms every time they buy or sell Establishment Labs'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Filippo Caldini over a week ago Disposition of 770 shares by Filippo Caldini of Establishment Labs at 34.82 subject to Rule 16b-3 | ||
Filippo Caldini over six months ago Insider Trading |
Establishment Labs Management Efficiency
The company has return on total asset (ROA) of (0.1015) % which means that it has lost $0.1015 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (2.3666) %, meaning that it created substantial loss on money invested by shareholders. Establishment Labs' management efficiency ratios could be used to measure how well Establishment Labs manages its routine affairs as well as how well it operates its assets and liabilities. As of March 23, 2025, Return On Tangible Assets is expected to decline to -0.27. The current year's Return On Capital Employed is expected to grow to -0.17. At present, Establishment Labs' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 7.7 M, whereas Total Assets are forecasted to decline to about 176.3 M.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Ryan Miller | LivaNova PLC | N/A | |
| Stanley Peters | CONMED | 45 | |
| Moshe Citronowicz | Apyx Medical | 72 | |
| Joel Becker | Integer Holdings Corp | 53 | |
| Paul Buckman | LivaNova PLC | 69 | |
| Joseph Hauser | Orthopediatrics Corp | 43 | |
| Daniel Gerritzen | Orthopediatrics Corp | 54 | |
| Stephanie Bolton | LivaNova PLC | 43 | |
| Keyna Skeffington | LivaNova PLC | 61 | |
| John Kennedy | CONMED | 66 | |
| Michael Sergesketter | Inogen Inc | 64 | |
| Payman Khales | Integer Holdings Corp | 55 | |
| MBAMSHA CHE | Orthopediatrics Corp | 53 | |
| Bart Sanford | Inogen Inc | 58 | |
| Franco Poletti | LivaNova PLC | N/A | |
| Tom Thomas | Integer Holdings Corp | 54 | |
| Carter Houghton | Integer Holdings Corp | 55 | |
| James Cunniff | Electromed | 59 | |
| Peter Shagory | CONMED | 56 | |
| David Bailey | Orthopediatrics Corp | 46 | |
| Johonna Pelletier | CONMED | 51 | |
Management Performance
| Return On Equity | -2.37 | ||||
| Return On Asset | -0.1 |
Establishment Labs Leadership Team
Elected by the shareholders, the Establishment Labs' board of directors comprises two types of representatives: Establishment Labs inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Establishment. The board's role is to monitor Establishment Labs' management team and ensure that shareholders' interests are well served. Establishment Labs' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Establishment Labs' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Juan Quiros, Founder Director | ||
| Heather Brennan, Head Operations | ||
| Roberto Mezerville, Chief Officer | ||
| Paul Rodio, Chief Officer | ||
| Jeff Ehrhard, Senior America | ||
| Jeff Ehrhardt, Senior America | ||
| Ivan Bilic, Senior OUS | ||
| Ross Mansbach, General Officer | ||
| Jeffrey Bettinger, Global People | ||
| Neeta Toprani, Corporate Secretary | ||
| Rosalyn dIncelli, Medical Clinical | ||
| Rajbir Denhoy, Chief Officer | ||
| Filippo Caldini, Interim President | ||
| Salvador Dada, Chief Officer | ||
| Elizabeth Newman, VP Unit |
Establishment Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Establishment Labs a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -2.37 | ||||
| Return On Asset | -0.1 | ||||
| Profit Margin | (0.51) % | ||||
| Operating Margin | (0.42) % | ||||
| Current Valuation | 1.28 B | ||||
| Shares Outstanding | 28.85 M | ||||
| Shares Owned By Insiders | 10.55 % | ||||
| Shares Owned By Institutions | 89.45 % | ||||
| Number Of Shares Shorted | 5.04 M | ||||
| Price To Earning | (20.11) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Establishment Labs Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Establishment Labs. If investors know Establishment will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Establishment Labs listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.00) | Revenue Per Share | Quarterly Revenue Growth 0.41 | Return On Assets | Return On Equity |
The market value of Establishment Labs is measured differently than its book value, which is the value of Establishment that is recorded on the company's balance sheet. Investors also form their own opinion of Establishment Labs' value that differs from its market value or its book value, called intrinsic value, which is Establishment Labs' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Establishment Labs' market value can be influenced by many factors that don't directly affect Establishment Labs' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Establishment Labs' value and its price as these two are different measures arrived at by different means. Investors typically determine if Establishment Labs is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Establishment Labs' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.